WUGEN Announces Exclusive License Agreement for CAR-T Therapy Technologies from Washington University in St. Louis
WUGEN Announces Presentations at American Society of Hematology Annual Meeting
An âoff-the-shelfâ fratricide-resistant CAR-T for the Treatment of T cell hematologic malignancies
T cell malignancies represent a group of hematologic cancers with high rates of relapse and mortality in patients for whom no effective targeted therapies exist. The shared expression of target antigens between chimeric antigen receptor (CAR) T cells and malignant T cells has limited the development.